Ксамиол is a topical preparation indicated for the management of plaque psoriasis (psoriasis vulgaris) in adult patients. Its authorized use is specifically for cases classified as stable, mild to moderate in severity, where the condition is amenable to local therapy. The primary therapeutic objective is to address the discomfort and visual signs associated with the plaques.

This medicine is used to help relieve the typical symptoms that define the condition, which include reducing inflammation, redness, scaling, and the characteristic thickness of the skin lesions. By targeting these symptoms, the treatment supports the patient’s overall skin comfort and well-being.

The preparation addresses conditions involving the scalp and non-scalp areas of the body, offering a focused approach to managing the localized effects of psoriasis.

---

Quick Fact: Relief for Psoriasis Symptoms

---

The official eligibility for Ксамиол (calcipotriol/betamethasone) is strictly defined by regulatory guidelines, primarily restricting use to certain patient populations and excluding others based on safety risks.

Who Can Use Ксамиол?

• Adults (18 years and older) for the topical treatment of plaque psoriasis.

Who Cannot Use Ксамиол?

The medicine is contraindicated in several groups due to its potent ingredients:

• Patients with disorders of calcium metabolism or with severe renal (kidney) or hepatic (liver) disorders.
• Individuals with specific forms of psoriasis, such as erythrodermic, exfoliative, or pustular psoriasis.
• Patients with active skin infections (viral, fungal, bacterial, or parasitic) or non-psoriasis skin conditions like rosacea, perioral dermatitis, or acne.
• Children and adolescents below 18 years of age are not recommended for use, as the safety and efficacy have not been established.

Use Restrictions

The medicine must not be applied to the face, groin, armpits, or areas where the skin is already thinned or atrophied. Use in pregnancy and during breastfeeding is restricted and only permitted if the potential benefit justifies the potential risk; it must not be applied to the breast area when nursing.

The official regulatory profile for Ксамиол defines specific restrictions and interaction patterns based on its dual active ingredients, calcipotriol and betamethasone.

Formal Restrictions and Contraindications

The medicine is formally restricted from use in patients who have documented disorders of calcium metabolism due to the influence of the calcipotriol component on systemic calcium levels. A primary restriction involves other steroid-containing products: concurrent treatment with other topical or systemic steroids must be avoided because it increases the total systemic exposure to the potent corticosteroid component. Patients are also required to limit or avoid excessive exposure to natural or artificial sunlight (UVR) during treatment due to the potential for photosensitivity.

Documented Pharmacological Interactions

Co-administration with Vitamin D analogues or calcium supplements is a relevant concern, as it may heighten the risk of elevated calcium levels (hypercalcaemia). The concentration of one of the active ingredients can be altered by certain co-administered drugs. For instance, the use of Phenytoin or Fosphenytoin is officially documented to result in a decreased serum concentration of calcipotriol. The steroid component may also affect blood sugar control; therefore, an interaction caution exists for patients taking anti-diabetic agents. Systemic absorption of the corticosteroid component is documented to increase when the medicine is applied under occlusive dressings.

How Ксамиол Works: Dual Mechanism of Action

Modulation of Keratinocyte Proliferation via VDR Agonism

This domain describes how calcipotriol binds to the Vitamin D Receptor (VDR) in skin cells. This molecular interaction initiates a signaling cascade that primarily targets the process of epidermal hyperproliferation. The mechanism slows the excessive division of skin cells and promotes their terminal differentiation (maturation), which results in the modulation of epidermal organization.

---

Suppression of Inflammatory and Immune Signaling

This second core domain is governed by betamethasone's agonism of the Glucocorticoid Receptor (GR), providing a significant anti-inflammatory effect. By suppressing the Arachidonic Acid cascade (through PLA2 inhibition) and repressing key pro-inflammatory cytokine genes, the mechanism blocks the creation and release of mediators associated with vasodilation and edema. This action leads to a rapid physiological suppression of the localized immune and vascular responses.

---

Mechanistic Synergy of Dual Pathological Targeting

The physiological effect of the combination relies on mechanistic synergy, where each ingredient targets a distinct component of the physiological dysregulation. Calcipotriol targets the long-term modulation of epidermal structure by correcting cell growth, while betamethasone offers rapid inflammatory suppression. This dual approach acts upon both the cellular kinetics and the immune-driven inflammation simultaneously.

How to Use Xamiol

Xamiol (calcipotriol/betamethasone dipropionate) is a combination medicine for topical use (cutaneous application). The administration of this treatment involves specific parameters regarding frequency and dosage limitations to ensure proper use.

Official Administration Guidelines

The standard regimen for adult patients requires application to the affected areas once daily. This frequency is typically used with a recommendation for evening application. The product is formulated as a topical gel and the bottle must be shaken before use to ensure the consistent distribution of the active ingredients.

Instruction Entity	Application Parameter
Administration Route	Topical use only.
Dosing Frequency	Once daily application.
Maximum Weekly Dose	Must not exceed 100 grams (of the combination product).
Treated Body Surface Area	Must not exceed 30% of the total body surface area.
Initial Treatment Duration	Generally limited to 4 weeks for scalp psoriasis.

Procedural Rules and Restrictions

To prevent unintentional spread, hands must be washed immediately after applying the gel, and application must be avoided on sensitive areas, including the face and eyes. The treatment course is time-limited, and its continuation beyond the initial duration requires medical review. For instance, the initial course for scalp psoriasis is typically four weeks. The product is not intended for use with occlusive dressings, which can increase systemic exposure. Furthermore, the safety and efficacy of the product have not been established for pediatric patients under 18 years of age or in patients with severe renal or hepatic impairment.

Research evidence / Overview of Studies for Ksamioł

Evidence for Use in Plaque Psoriasis (Psoriasis Vulgaris)

The primary research for Ksamioł involves multiple large-scale Randomized Controlled Trials (RCTs). These studies were used in the research context to explore how the fixed-dose combination product, available as a topical gel or ointment, was evaluated against the individual components (calcipotriol alone or betamethasone alone) or an inactive vehicle (placebo). The research focused mainly on adults diagnosed with mild-to-moderate chronic plaque psoriasis.

These studies monitored specific clinical outcomes, such as the proportion of patients whose psoriasis was judged as "Clear" or "Almost Clear" by an investigator, and changes in scores reflecting the severity, extent, and thickness of the skin plaques. Studies monitored these changes over defined time intervals, typically within the range of four to eight weeks. Studies reported patterns where the combination product was evaluated against the individual active components and the non-medicated vehicle in achieving the pre-defined clinical outcomes. Findings indicated observed differences in the achievement of these outcomes. Research also includes findings related to patient-reported outcomes, describing perceived discomfort and impact on daily functioning or activity level.

---

Evidence for Use in Scalp Psoriasis

Specific research has been dedicated to studying Ksamioł in a research context involving the scalp area. These studies are relevant in trials assessing short-term symptom patterns in patients with scalp psoriasis. The evidence base includes studies that monitored outcomes over follow-up durations extending up to 52 weeks.

Research examined symptomatic measures, such as assessments of redness, scaling, and thickness, and reported how these symptoms changed in the observed populations with scalp involvement. Findings include patient-reported outcomes describing their experience following application to the scalp.

---

What is Still Uncertain About the Research

While a significant amount of high-quality evidence exists for the short-term use in adults, certain aspects remain uncertain or are supported by less robust data. Extensive, multi-year controlled trials are limited. Evidence quality varies across the available long-term observational studies. Furthermore, the data for certain groups, such as adolescent patients, remains insufficient when compared to the adult evidence base, as studies in this younger population have generally featured smaller sample sizes and lacked a control group.

Key Studies & References

1. Calcipotriene and Betamethasone Dipropionate Topical: MedlinePlus Drug Information

Common questions about Ксамиол (FAQ)

---

Q: Is Ксамиол the same as Daivobet gel or ointment?

Official product information indicates that Ксамиол is a brand name for the combination product containing calcipotriol and betamethasone. It is considered pharmaceutically equivalent to Daivobet in many regions, meaning they contain the same two active ingredients in the same strengths.

---

Q: Can I use Ксамиол on my scalp as well as my body?

Official regulatory documents indicate that the gel formulation of this combination product is approved for the topical treatment of psoriasis on the scalp and for mild-to-moderate plaque psoriasis on non-scalp areas of the body.

---

Q: What happens if I stop using Ксамиол suddenly?

Regulatory warnings, due to the potent corticosteroid component (betamethasone), state that treatment should be discontinued gradually. This measure is intended to help reduce the risk of a rebound effect (exacerbation of the skin condition) upon stopping use.

---

Q: Can Ксамиол cause changes in skin pigmentation?

Official product information notes that changes in skin pigmentation (patches of lighter or darker skin) have been reported as possible side effects associated with the corticosteroid component. The exact frequency of this reaction is not always stated as common.

---

Q: Is it safe to use Ксамиол while taking vitamins or supplements?

Official information advises caution regarding certain supplements. The medicine is contraindicated or requires specific precaution if used concurrently with calcium supplements or other medicines containing Vitamin D analogues. This precaution is taken because the calcipotriol component has the potential to raise the risk of hypercalcaemia (elevated calcium levels in the blood).

---

Q: Is Ксамиол safe for elderly patients?

Regulatory information states the product is for adults (18 years and older). While there are no specific dosage adjustments for age alone, the medicine is contraindicated in patients with severe underlying renal (kidney) or hepatic (liver) disorders.

---

Q: How long after applying Ксамиол should I wait before showering?

Official instructions specify that the medicine should be applied only once daily and that the treated area should not be washed immediately after application. The regulatory intent is to allow sufficient time for the medication to be absorbed into the skin.

---

Q: What if I miss a dose of Ксамиол?

Official patient instructions indicate that a missed dose should be applied as soon as it is remembered. However, the maximum weekly dosage limit established in regulatory documents must always be respected; therefore, applying a double dose is not permitted.

---

Q: Can Ксамиол make my skin more susceptible to bruising?

Due to the potent corticosteroid component, official safety information lists potential local side effects such as skin thinning and an increased tendency toward bruising (known as purpura). These effects are generally considered uncommon.

---

Q: Why do people sometimes say Ксамиол is very potent?

The perception of potency is likely related to its composition, as official regulatory documents explicitly classify one of the active ingredients, betamethasone, as a potent corticosteroid. This classification highlights its high pharmacological strength and anti-inflammatory activity.

---

Q: Can Ксамиол cause hair thinning or loss on the scalp?

Official safety information for this class of medicine notes potential local reactions like folliculitis (inflammation of the hair follicles) as an uncommon side effect. While not always detailed, long-term use of potent corticosteroids is generally associated with potential changes in hair growth patterns.

---

Q: Are there any known interactions between Ксамиол and herbal remedies?

Formal regulatory documents usually do not list specific interactions with herbal remedies. This indicates that the effect of these combinations has not been established in required pharmacological studies, which limits official guidance on co-administration.

---

Q: What does 'topical use only' mean for Ксамиол?

'Topical use only' means the medicine is strictly intended for application onto the surface of the skin (cutaneous use). Regulatory guidelines emphasize that the medicine is restricted from being swallowed, injected, or used internally in any other way.

---

Q: Has Ксамиол been tested for its effect on driving or operating machinery?

Regulatory documents explicitly state that the medicine has no or negligible influence on a person's ability to drive or operate heavy machinery. This is because the medication acts locally and is not associated with systemic central nervous system effects.

---

How to Store and Dispose of Xamiol Gel

Xamiol (calcipotriol/betamethasone) gel must be stored according to specific regulatory requirements to maintain its stability.

Storage Conditions

Temperature and Protection

The medicine must be stored below 25°C (77°F). It is prohibited to refrigerate or freeze the gel. The container must be kept in the outer carton to protect it from light.

Stability and Safety

Once the tube is first opened, the medicine must be used within 6 months. As a standard safety requirement, keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired medicinal product and waste material must be disposed of in accordance with local requirements. The gel should not be disposed of via wastewater or household waste.